Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109606

Purinogenic Immunodeficiency Diseases: DIFFERENTIAL EFFECTS OF DEOXYADENOSINE AND DEOXYGUANOSINE ON DNA SYNTHESIS IN HUMAN T LYMPHOBLASTS

James M. Wilson, Beverly S. Mitchell, Peter E. Daddona, and William N. Kelley

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109

Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109

Find articles by Wilson, J. in: PubMed | Google Scholar

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109

Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109

Find articles by Mitchell, B. in: PubMed | Google Scholar

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109

Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109

Find articles by Daddona, P. in: PubMed | Google Scholar

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109

Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109

Find articles by Kelley, W. in: PubMed | Google Scholar

Published November 1, 1979 - More info

Published in Volume 64, Issue 5 on November 1, 1979
J Clin Invest. 1979;64(5):1475–1484. https://doi.org/10.1172/JCI109606.
© 1979 The American Society for Clinical Investigation
Published November 1, 1979 - Version history
View PDF
Abstract

Deoxyadenosine and deoxyguanosine are toxic to human lymphoid cells in culture and have been implicated in the pathogenesis of the immunodeficiency states associated with adenosine deaminase and purine nucleoside phosphorylase deficiency, respectively. We have studied the relative incorporation of several labeled nucleosides into DNA and into nucleotide pools to further elucidate the mechanism of deoxyribonucleoside toxicity. In the presence of an inhibitor of adenosine deaminase [erythro-9-(2-hydroxy-3-nonyl)adenine [EHNA], 5 μM], deoxyadenosine (1-50 μM) progressively decreased the incorporation of thymidine, uridine, and deoxyuridine into DNA, but did not affect uridine incorporation into RNA. This decrease in DNA synthesis was associated with increasing dATP and decreasing dCTP pools. Likewise, incubation of cells with deoxyguanosine caused an elevation of dGTP, depletion of dCTP, and inhibition of DNA synthesis.

To test the hypothesis that dATP and dGTP accumulation inhibit DNA synthesis by inhibiting the enzyme ribonucleotide reductase, simultaneous rates of incorporation of [3H]uridine and [14C]thymidine into DNA were measured in the presence of deoxyadenosine plus EHNA or deoxyguanosine, and in the presence of hydroxyurea, a known inhibitor of ribonucleotide reductase. Hydroxyurea (100 μM) and deoxyguanosine (10 μM) decreased the incorporation of [3H]uridine but not of [14C]thymidine into DNA; both compounds also substantially increased [3H]cytidine incorporation into the ribonucleotide pool while reducing incorporation into the deoxyribonucleotide pool. In contrast, deoxyadenosine plus EHNA did not show this differential inhibition of [3H]uridine incorporation into DNA, and the alteration in [3H]cytidine incorporation into nucleotide pools was less impressive.

These data show an association between accumulation of dATP or dGTP and a primary inhibition of DNA synthesis, and they provide support for ribonucleotide reductase inhibition as the mechanism responsible for deoxyguanosine toxicity. Deoxyadenosine toxicity, however, appears to result from another, or perhaps a combination of, molecular event(s).

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1475
page 1475
icon of scanned page 1476
page 1476
icon of scanned page 1477
page 1477
icon of scanned page 1478
page 1478
icon of scanned page 1479
page 1479
icon of scanned page 1480
page 1480
icon of scanned page 1481
page 1481
icon of scanned page 1482
page 1482
icon of scanned page 1483
page 1483
icon of scanned page 1484
page 1484
Version history
  • Version 1 (November 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts